PLXNA1

Across TCGA pan-cancer cohorts, PLXNA1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLXNA1 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLXNA1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLXNA1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PLXNA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.318	0.451	.018	13	view →
LUAD	DFS	Median	II,III,IV	0.888	0.780	.026	3	view →
GBM	DFS	Quartile	All	0.863	0.693	.040	2	view →
HNSC	DFS	Median	All	0.977	0.927	.048	2	view →
CCRCC	DFS	Median	III,IV	0.438	0.706	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLXNA1–PDAC (DFS)

Open the PDAC breakdown →